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Chronic norovirus infection is a risk factor for secondary lactose intolerance
in renal transplant recipients. A case-control study
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Abstract: Nierentransplantierte leiden gehäuft unter chronischer Diarrhoe. Diese könnte durch die chro-
nische Besiedelung mit Norovirus mitverursacht sein. Ziel der vorliegenden Arbeit war es, bei Nierentrans-
plantierten mit Durchfall die Inzidenz einer Laktosemaldigestion bei nierentransplantierten Patienten mit
symptomatischer chronischer Norovirusinfektion im Vergleich zu Transplantierten mit chronischer Diar-
rhoe aufgrund einer anderen Ursache zu untersuchen. Es wurden 15 nierentransplantierte Patienten
untersucht. Davon hatten 7 eine chronische Norovirusinfektion mit Diarrhöe und 8 hatten Diarrhoe
ohne Norovirus (Kontrollgruppe). Der Laktoseintoleranztest war positive bei allen 7 Patienten (100%)
in der Norovirusgruppe, jedoch nur bei 1 von 8 Patienten (12.5%) in der Kontrollgruppe (odds ratio
75.0 (95% CI 2.6, 2153, p=0.01). Zusammenfassend wird gezeigt, dass es eine eindeutige Korrelation
zwischen chronischer Norovirusinfektion und Laktoseintoleranz gibt, was dafür spricht dass die Diar-
rhoe bei immunsupprimierten Patienten mit einer chronischen Norovirusinfektion durch eine sekundäre
Laktosemaldigestion hervorgerufen oder unterhalten werden könnte.
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IBS, irritable bowel syndrome  
IQR, interquartile range 
LHBT, lactose hydrogen breath test  
LTT, lactose tolerance test  
LCT, lactase 
LI, lactose intolerance 
LM, lactose maldigestion 
PCR, polymerase chain reaction  
RTR, renal transplant recipient  
PCR, polymerase chain reaction 
SIBO, small intestine bacterial overgrowth  
  






Background: Chronic norovirus infection is an emerging challenge in the immunocompromised 
host, in whom it may be asymptomatic or present as chronic diarrhea. The mechanisms of 
diarrhea in chronic norovirus infection are not well understood, but in analogy to Gardia lamblia 
and rotavirus infections, secondary lactose maldigestion (LM) might be implicated. 
Methods: Adult renal transplant recipients (RTRs) who had symptomatic chronic norovirus 
infection with diarrhea were asked to participate in this prospective parallel cohort study. RTRs 
with otherwise unexplainable chronic diarrhea but absent infection served as control group. In 
both groups, a lactose hydrogen breath test (LHBT) and a lactose tolerance test (LTT) were 
performed after exclusion of primary LM by a negative lactase gene test. 
Results: Of approximately 800 patients in the cohort of RTRs at our institution, 15 subjects were 
included in the present study. Of these, 7 had chronic symptomatic norovirus infection with 
diarrhea (noro group) and 8 had diarrhea in the absence of norovirus (control group). LHBT and 
LTT were positive in all 7 patients (100%) in the noro group, whereas only 1 of 8 patients 
(12.5%) in the control group had a positive test. Thus, secondary LM was highly prevalent in the 
noro compared to the control group with an odds ratio of 75.0 (95% CI 2.6, 2153, p=0.01). 
Conclusions: This is the first report showing a positive association of chronic norovirus infection 
and secondary LM. Further studies with larger patient numbers and longer follow-up are needed 
to test a causative relationship between both entities. 
 
Key Words: Chronic norovirus infection, chronic diarrhea, renal transplant recipients, lactose 
maldigestion  






Norovirus, a single-stranded RNA virus of the Caliciviridae family, is a human enteric 
pathogen that is 1 of the leading causes of acute gastroenteritis, presenting as self-limited disease 
of short duration in immunocompetent subjects.1-3 However, chronic norovirus infection is an 
emerging challenge in the immunocompromised host such as leukemia patients or solid organ 
transplant recipients, in whom the virus may persist and present as chronic diarrhea and diffuse 
abdominal discomfort, and may even be associated with kidney transplant dysfunction.4-8 
Norovirus accounts for 17-26% of severe posttransplant diarrhea in renal transplant 
recipients.5,6,9 Norovirus related diarrhea is associated with the greatest weight loss compared to 
other causes of diarrhea.5,9 Histologically, signs of chronic intestinal inflammation are present.4,5 
Until now, the mechanisms of diarrhea in case of chronic norovirus infection are not well 
understood, and treatment options are limited. 
Lactose is a disaccharide and a frequent constituent of a typical Western-type diet. Lactose 
maldigestion (LM) refers to inefficient cleavage of lactose in the small intestine, resulting in 
lactose malabsorption and fermentation of lactose by the colonic microbiota. In contrast, lactose 
intolerance (LI) is defined as the development of symptoms after lactose challenge in individuals 
with LM.10 LM is a frequent condition, affecting more than 50% of all individuals worldwide 
and should be regarded a variant of human intestinal physiology.11 Primary LM is typically 
associated with the CC polymorphism of the -13910 locus of the lactase (LCT) gene.12 In 
contrast, secondary LM can develop in many intestinal inflammatory conditions; however, which 
specific conditions will lead to LM as well as mechanistic aspects, have not been sufficiently 
clarified. 





In a prospective study in children with acute gastroenteritis, a significant proportion was found to 
have LM, which was most commonly associated with rotavirus infection.13 Secondary LM has 
also been reported in patients with Giardia lamblia infections, and the latter were shown to alter 
the cellular glycocalyx resulting in alterations of brush border disaccharidase enzymes.14,15 In 
line with these findings we suspect a similar mechanism in symptomatic patients with chronic 
norovirus infections. The objective of this study was therefore to determine the prevalence of 
secondary LM in patients with chronic norovirus infection. 
 
Materials and Methods 
Subjects 
Between July 2013 and March 2015 all adult renal transplant recipients (RTRs) at the 
University Hospital Zürich who had symptomatic chronic norovirus infection with diarrhea were 
asked to participate in this prospective parallel cohort study. According to the WHO-approved 
definition of diarrhea we chose the cut-off of 3 or more bowel movements per day for more than 
4 weeks as indicative of chronic diarrhea. Chronic norovirus infection was proven by positive 
polymerase chain reaction (PCR) analysis of recent stool samples, whereas chronic virus 
shedding was defined as more than 2 PCR positive samples at an interval of at least 1 month. 
Concomitant viral (ie cytomegalovirus), bacterial (ie Salmonella spp., Campylobacter spp., 
Shigella spp., and C.difficile) and parasitic (Gardia lamblia, Microspora spp., and Cryptospora 
spp.) intestinal infections were excluded by negative stool PCR analyses, stool cultures, and 
direct microscopic stool examinations, respectively. Furthermore, CMV viremia was excluded 
by PCR technique. Main exclusion criterion for the present study was a concomitant intestinal 
infection (other than norovirus), and primary LM which was previously excluded by absence of 





the CC genotype of the DNA variant -13910 T/C upstream in the LCT gene. Subjects with a 
proven galactosemia or those requiring a low galactose diet were also excluded. RTRs with 
otherwise unexplainable chronic diarrhea but absent norovirus or another intestinal infection, and 
negative LCT gene test served as control group. In both groups, a lactose hydrogen breath test 
(LHBT) and a lactose tolerance test (LTT) were performed in all eligible RTRs (Figure 1). LM 
was diagnosed with a positive LHBT and/or a positive LTT.  
Written informed consent was obtained from all patients included in the study. The study 
was approved by the local Ethics committee (KEK-ZH 2012-0473) and is registered at 
ClinicalTrials.gov (identifier: NCT01840891). 
 
 Lactose H2 breath test (LHBT) 
The LHBT was performed according to the Rome consensus conference.16 After an 
overnight fast of at least 12 hours, a basal breath sample was collected. No individual showed a 
baseline hydrogen (H2) level above 20 ppm (not shown). RTRs were allowed to drink water and 
follow their usual medication regimen during the entire examination. After collecting the 
baseline sample, RTRs were given 25 g of lactose dissolved in 250 ml of water to drink. Orange 
flavored lactose powder (or milk powder) was provided with the AlveoSampler™ Lactose Kit 
(Quintron Instrument Co., Milwaukee, WI, USA). Samples of end expiratory breath were then 
collected at 30, 60, 90 and 120 minutes after the oral lactose load to measure the concentration of 
H2, which was considered significantly increased and indicative of LM when exceeding 20 
ppm.16,17 During the test, RTRs were allowed to engage in normal activities, but were kept 
fasting except for water consumption which was permitted throughout the examination. The test 
was performed in a well-ventilated room free of fresh painted walls or objects and with no 





evidence of any organic solvents or cigarette smoke. The breath samples were collected in 
specially constructed bags, which are provided along with the instrument. Exhaled breath H2 was 
measured on a Model 12i Microlyser (Quintron Instrument Co., Milwaukee, WI, USA). The 
number of loose bowel motions and flatulence during the test were also documented. 
 
Lactose tolerance test (LTT) 
Following the above mentioned oral administration of 25 g lactose, capillary blood 
glucose levels were measured at 0, 60, and 120 minutes, by using a glucometer (Ascensia 
Contour, Bayer AG, Leverkusen, Germany). An increase of blood glucose by less than 1.1 




Baseline data are reported as median (interquartile range, IQR), or numbers (percentages) 
as appropriate. Differences in baseline characteristics and between the 2 study groups were 
estimated using the Mann-Whitney U test for continuous variables and the χ2 test for categorical 
variables. Values of exhaled breath hydrogen concentrations and blood glucose are presented as 
median (interquartile range, IQR). Differences of these values between different points in time 
were calculated using the paired sample Wilcoxon signed rank test. P-values of all outcomes 
were 2-sided; values less than 0.05 were considered to indicate statistical significance. All 
statistical analyses were performed using IBM SPSS Statistics for Windows, version 22 (IBM 
Corporation, Armonk, NY). 
 






Of approximately 800 patients in the cohort of adult RTRs at the University Hospital 
Zürich, 22 individuals were identified with chronic diarrhea, 15 of which could be included in 
the present study (Figure 1). Four individuals were excluded due to primary LM in line with an 
expected frequency of primary LM in Switzerland of 20-40%11 Seven of these 15 individuals had 
chronic symptomatic norovirus infection with diarrhea with the genotype G2.4 (noro group), and 
8 patients had diarrhea in the absence of norovirus infection and served as control group. 
Baseline characteristics of the subjects in both groups are shown in Table 1, and laboratory data 
are summarized in Table 2. Cytomegalovirus high risk constellation (CMV donor/recipient 
serostatus D+/R-) was significantly more prevalent in the control group (p=0.013). However, the 
onset of diarrhea before study inclusion was significantly earlier in the noro group (p=0.038). 
Other variables, such as age, sex, mode and dose of immunosuppression, prevalence of diabetes 
mellitus, and laboratory values were comparable in both groups. At the moment of the testing, no 
patient was treated with antibiotics, and CMV PCR was negative in all patients. As part of the 
clinical routine diagnostic in transplanted patients with chronic diarrhea, 6 patients (85.7%) in 
the norovirus group had a colonoscopy. In all patients, the histology showed chronic 
inflammatory changes. CMV-colitis was specifically excluded with histology and 
immunohistochemistry of biopsy specimens. The final diagnosis of chronic diarrhea in those 
patients without evidence of norovirus infection was mycophenolate-associated colitis in 3 and 
unknown etiology or diabetes mellitus in 5 cases. 
   
In the noro group, all patients had a positive LHBT. In the control group, only 1 patient (12.5%) 
had a positive test (Table 3). Accordingly, the increase of the median exhaled H2 content 





between baseline (7.0 (2.0, 11.0) ppm) and 120 minutes after lactose ingestion (35.5 (10.0, 66.2) 
ppm) in the noro group was significant (p=0.043) (Figure 2). By contrast, in the control group H2 
values only a minor, nonsignificant increase between baseline (4.0 (1.2, 6.0) ppm) and after 
lactose exposure was observed (9.0 (4.0, 16.2) ppm) (p=0.063) and all values remained below 
the threshold of 20ppm. 
Analogously, LTT was positive in all patients in the noro group, whereas only the above 
mentioned patient in the control group had a positive test (Table 3). However, in both groups the 
increase of blood glucose between baseline and 60 min after lactose ingestion was significant 
(Figure 3), although the difference was more pronounced in the control group (baseline 5.3 (5.1, 
6.6) mmol/l; after 60 min 7.9 (5.9, 8.5) mmol/l) (p=0.017) compared to the noro group (baseline 
5.4 (4.8, 5.5) mmol/l; after 60 min 6.4 (5.7, 7.0) mmol/l) (p=0.046). 
In all but 1 patient of the noro group, there were abdominal symptoms after lactose ingestion 
(diarrhea, n=2; bloating, n=3; combination of diarrhea and bloating, n=1). In the control group, 
no patient reported abdominal symptoms (Table 3). The patient in the control group with positive 
LHBT and LTT denied any symptoms after lactose ingestion. 
Based on both tests, secondary LM was highly prevalent in the noro group compared to the 
control group with an odds ratio of 75.0 (95% CI 2.6, 2153), p=0.01. Likewise, for secondary LI 
(defined as LM with symptoms), the odds ratio was 73.7 (95% CI 2.6, 2120), p=0.01 (Table 3). 
 
Discussion 
Chronic norovirus infection is an emerging challenge in the immunocompromised host, in 
whom it may present as chronic diarrhea. The aim of the present study was to investigate 





whether secondary LM can contribute to diarrhea in patients with chronic norovirus shedding. 
This is the first report showing a positive association of chronic norovirus infection in RTRs and 
secondary LM, suggesting a causative relationship between both entities. In addition, LI was 
highly prevalent, and diarrhea lasted substantially longer in RTRs with symptomatic chronic 
norovirus infection. Thus, secondary LM due to chronic norovirus infection could possibly be 
another cause of chronic diarrhea beside drug-induced diarrhea (eg mycophenolate) in 
immunosuppressed patients. Schorn et al found in their case series of RTRs with chronic 
norovirus infection, that the intensity of immunosuppression correlated with diarrheal symptoms 
but not with viral shedding.6 Thus, immunosuppression dosage is maybe the most important risk 
factor for chronic norovirus infection. Therefore, we generally follow a stepwise approach with 
first reducing the dosage of mycophenolate because of the possibility of a coincident 
mycophenolate toxicity contributing to the chronic diarrhea, followed by reduction of the 
calcineurin-inhibitor dosage and attempt to taper/stop prednisone therapy. In our study, 
immunosuppressant dosage was similar in both groups in our study. However, lymphocyte 
counts were significantly lower in the noro group.  
In general, endoscopy was performed for ongoing chronic diarrhea to rule out other conditions. 
However, colonoscopy was not an inclusion criterion in this study, although most of the patients 
had the procedure performed prior to study inclusion. Our standard procedure in RTR’s with 
chronic diarrhea is CMV-PCR in blood, stool cultures for bacteria including Clostridium difficile 
and Clostridium toxin detection, PCR analysis of stool specimens for norovirus, and microscopy 
for parasites such as Microsporidium and Cryptosporidium. If the tests are negative, and the 
diarrhea persists, we first reduce the mycophenolate doses or change to enteric coated 
mycophenolic acid and try to reduce the cumulative immunosuppressive dosage according to the 





immunological risk. If the diarrhea still persists, patients underwent a colonoscopy to look for 
other causes such as CMV colitis or mycophenolate toxicity.   
LHBT is a standard diagnostic test for LM in clinical practice. However, 2 potential limitations 
should be mentioned: Small intestine bacterial overgrowth (SIBO) with lactose fermentation and 
H2 production in the small intestine could potentially lead to a false positive LHBT. However, 
SIBO and LM can be distinguished, since the resulting H2 peak will be early in the former (small 
bowel peak), but delayed and more prominent in the latter (colonic peak).18 Furthermore, in a 
variable fraction of individuals (2-43%, <10% in most studies) the bowel flora does not produce 
H2, leading to a false negative LHBT.16 
Limitations of LTT include fluctuations of blood sugar levels for instance due to impaired 
glucose tolerance, diabetes or other influences.19 The small increase in blood sugar levels 
required for a positive test will thus result in an inferior sensitivity and specificity of LTT, 
therefore this test is not recommended as a routine diagnostic test for LM.10,20 However, since 
limitations of LHBT and LTT are largely nonoverlapping these tests can complement each other. 
In our study we found a perfect agreement of both tests regarding LM, arguing for the validity of 
our results. 
Importantly, in the noro group but not in the control group, patients reported symptoms after 
lactose ingestion, suggesting that patients with chronic norovirus infection in fact suffer from LI. 
For most individuals with LM, a blinded challenge with 25 g of lactose does not result in any 
symptoms.21 Therefore, symptoms after lactose ingestion in individuals with LM are likely due 
to the concomitant presence of visceral hypersensitivity, for instance due to irritable bowel 
syndrome (IBS). This was also suggested in a blinded controlled study where a challenge with 20 





g lactose resulted in typical symptoms in 47% of patients with IBS but only in 22% of control 
patients.22 Postinfectious IBS has been reported as a complication of viral gastroenteritis.23 Our 
patients were not formally tested for the presence of IBS. However, our data suggest that visceral 
hypersensitivity can also complicate chronic norovirus infection. 
Secondary LM has been reported in patients with intestinal inflammation due to other chronic 
inflammatory conditions including Crohn’s disease.24,25 In a rat model of mucositis, lactose 
digestion was severely reduced, along with downregulation of lactase mRNA and protein levels, 
while glucose absorption remained intact.26 In this study, other intestinal disaccharidases were 
also downregulated, suggesting that lactase might be a marker for a more general derangement of 
digestive enzymes. Clearly, an isolated downregulation of lactase does not explain chronic 
diarrhea in norovirus infected patients since most individuals with primary LM are free of 
symptoms. Therefore, further mechanistic studies regarding the expression of lactase levels and 
other disaccharidases are clearly needed. 
We are conscious that our study has several limitations. First, the sample size is small which is 
due to the low prevalence of symptomatic chronic norovirus infection. Secondly, since our study 
focused on RTRs the results might not be extrapolated to other immunocompromised disease 
states in which chronic norovirus infection is a relevant concern.8 Thirdly, the investigators were 
not blinded for the results of norovirus PCR before lactose tolerance testing and no blinded 
placebo control was done as suggested by an NIH conference addressing LI.27 Thus, placebo 
effects for the development of symptoms cannot be totally excluded. Finally, no additional tests 
regarding intestinal malabsorption were performed and our study does not provide a 
comprehensive information regarding all aspects of intestinal malfunction in norovirus infection.  
 






This is the first study to show a positive association between chronic norovirus infection 
and secondary LM in RTRs. Future studies should address whether a lactose-reduced diet might 










1. Ahmed SM, Hall AJ, Robinson AE, et al. Global prevalence of norovirus in cases of 
gastroenteritis: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14:725-
730. 
2. Robilotti E, Deresinski S, Pinsky BA. Norovirus. Clin Microbiol Rev. 2015;28:134-164. 
3. Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N Engl J Med. 
2009;361:1776-1785. 
4. Westhoff TH, Vergoulidou M, Loddenkemper C, et al. Chronic norovirus infection in 
renal transplant recipients. Nephrol Dial Transplant. 2009;24:1051-1053. 
5. Roos-Weil D, Ambert-Balay K, Lanternier F, et al. Impact of norovirus/sapovirus-related 
diarrhea in renal transplant recipients hospitalized for diarrhea. Transplantation. 
2011;92:61-69. 
6. Schorn R, Hohne M, Meerbach A, et al. Chronic norovirus infection after kidney 
transplantation: molecular evidence for immune-driven viral evolution. Clin Infect Dis. 
2010;51:307-314. 
7. Capizzi T, Makari-Judson G, Steingart R, Mertens WC. Chronic diarrhea associated with 
persistent norovirus excretion in patients with chronic lymphocytic leukemia: report of 
two cases. BMC Infect Dis. 2011;11:131. 
8. Bok K, Green KY. Norovirus gastroenteritis in immunocompromised patients. N Engl J 
Med. 2012;367:2126-2132. 
9. Coste JF, Vuiblet V, Moustapha B, et al. Microbiological diagnosis of severe diarrhea in 
kidney transplant recipients by use of multiplex PCR assays. J Clin Microbiol. 
2013;51:1841-1849. 





10. Misselwitz B, Pohl D, Fruhauf H, Fried M, Vavricka SR, Fox M. Lactose malabsorption 
and intolerance: pathogenesis, diagnosis and treatment. United European Gastroenterol 
J. 2013;1:151-159. 
11. Itan Y, Jones BL, Ingram CJ, Swallow DM, Thomas MG. A worldwide correlation of 
lactase persistence phenotype and genotypes. BMC Evol Biol. 2010;10:36. 
12. Enattah NS, Sahi T, Savilahti E, Terwilliger JD, Peltonen L, Jarvela I. Identification of a 
variant associated with adult-type hypolactasia. Nat Genet. 2002;30:233-237. 
13. Gonzalez-Galan V, Sanchez-Fauqier A, Obando I, et al. High prevalence of community-
acquired norovirus gastroenteritis among hospitalized children: a prospective study. Clin 
Microbiol Infect. 2011;17:1895-1899. 
14. Rana SV, Bhasin DK, Vinayak VK. Lactose hydrogen breath test in Giardia lamblia-
positive patients. Dig Dis Sci. 2005;50:259-261. 
15. Khanna R, Vinayak VK, Mehta S, KumKum, Nain CK. Giardia lamblia infection in 
immunosuppressed animals causes severe alterations to brush border membrane enzymes. 
Dig Dis Sci. 1988;33:1147-1152. 
16. Gasbarrini A, Corazza GR, Gasbarrini G, et al. Methodology and indications of H2-
breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment 
Pharmacol Ther. 2009;29 Suppl 1:1-49. 
17. Newcomer AD, McGill DB, Thomas PJ, Hofmann AF. Prospective comparison of 
indirect methods for detecting lactase deficiency. N Engl J Med. 1975;293:1232-1236. 
18. Romagnuolo J, Schiller D, Bailey RJ. Using breath tests wisely in a gastroenterology 
practice: an evidence-based review of indications and pitfalls in interpretation. Am J 
Gastroenterol. 2002;97:1113-1126. 





19. Arola H. Diagnosis of hypolactasia and lactose malabsorption. Scand J Gastroenterol 
Suppl. 1994;202:26-35. 
20. Terjung B, Lammert F. [Lactose intolerance: new aspects of an old problem]. Dtsch Med 
Wochenschr. 2007;132:271-275. 
21. Suarez FL, Savaiano DA, Levitt MD. A comparison of symptoms after the consumption 
of milk or lactose-hydrolyzed milk by people with self-reported severe lactose 
intolerance. N Engl J Med. 1995;333:1-4. 
22. Yang J, Deng Y, Chu H, et al. Prevalence and presentation of lactose intolerance and 
effects on dairy product intake in healthy subjects and patients with irritable bowel 
syndrome. Clin Gastroenterol Hepatol. 2013;11:262-268 e261. 
23. Zanini B, Ricci C, Bandera F, et al. Incidence of post-infectious irritable bowel syndrome 
and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. 
Am J Gastroenterol. 2012;107:891-899. 
24. Mishkin B, Yalovsky M, Mishkin S. Increased prevalence of lactose malabsorption in 
Crohn's disease patients at low risk for lactose malabsorption based on ethnic origin. Am 
J Gastroenterol. 1997;92:1148-1153. 
25. Kirschner BS, DeFavaro MV, Jensen W. Lactose malabsorption in children and 
adolescents with inflammatory bowel disease. Gastroenterology. 1981;81:829-832. 
26. Fijlstra M, Rings EH, Verkade HJ, van Dijk TH, Kamps WA, Tissing WJ. Lactose 
maldigestion during methotrexate-induced gastrointestinal mucositis in a rat model. Am J 
Physiol Gastrointest Liver Physiol. 2011;300:G283-291. 





27. Suchy FJ, Brannon PM, Carpenter TO, et al. NIH consensus development conference 









Figure 1. Study flow chart 
 
LHBT, lactose H2 breath test; LTT, lactose tolerance test 
 
Figure 2. Lactose H2 breath test 
 
Exhaled H2 content before and after ingestion of 25 g lactose 
 
Figure 3. Lactose tolerance test 
 
Serum glucose before and after ingestion of 25 g lactose 
 
  











































Age, years 52 (47, 60) 50 (34, 56) 0.46 
Male sex 6 (75) 4 (57) 0.46 
BMI, kg/m
2 24.8 (23.2, 26.5) 22.2 (17.0, 24.4) 0.09 
Time since transplantation, years 2 (1-4) 6 (2-9) 0.23 
RTx/RPTx 7/1 5/2 0.44 
Immunosuppression, n (median daily 
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CMV risk constellation 
- High (D+/R-) 
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Diabetes mellitus 3 (38) 2 (12) 0.31 
 





Data are presented as median (interquartile range), or numbers (percent). BMI, body mass index; 
CMV, cytomegalovirus; PCR, polymerase chain reaction; RTx, renal transplantation; RPTx, 
combined renal-pancreatic transplantation  





Table 2. Baseline laboratory values 






Hemoglobin, g/l 135 (118, 147) 122 (106, 133) 0.46 
Leucocytes, G/l 6.1 (4.8, 6.9) 4.1 (4.0, 6.0) 0.12 
Lymphocytes, G/l 1.42 (0.93-1.61) 1.00 (0.57-1.05) 0.041 
Alanine transaminase, U/l 20 (14, 24) 22 (17, 37) 0.28 
Alkaline phosphatase, U/l 56 (55, 81) 80 (55, 92) 0.71 
Estimated glomerular filtration rate*, 
ml/min/1.73 m2 
48 (43, 58) 43 (40, 48) 0.40 
Potassium, mmol/l 4.1 (4.0, 4.1) 4.4 (3.8, 4.8) 0.40 
Sodium, mmol/l 140 (138, 140) 141 (139, 143) 0.28 
Glucose, mmol/l 5.4 (4.8, 6.0) 5.1 (5.0, 5.5) 0.69 
C-reactive protein, mg/l 0.9 (0.6, 1.5) 0.4 (0.3, 0.5) 0.054 
 
Data are presented as median (interquartile range). * CKD-EPI equation.  
 
  





Table 3. Test results of LHBT and LTT 
 Noro group (n=7) Control group (n=8) 
LHBT / LTT positive 7 (100)* 1 (12.5)* 
GI symptoms after lactose 6 (85.7)# 0 (0) # 
 
Values are displayed in n (%). * p=0.001; # p=0.057. 
GI, gastrointestinal; LHBT, lactose H2 breath test; LTT, lactose tolerance test 
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Eine chronische Norovirus-Infektion mit Viruspersistenz geht oft mit einer 
chronischen Diarrhoe und Abdominalbeschwerden einher. Deren Pathogenese ist 
bislang nicht genau geklärt. Bei Infektionen durch Rotaviren und Giardia lamblia 
wurde eine Laktosemaldigestion bzw. eine Schädigung der Dünndarmschleimhaut 
mit einem Verlust von Disaccharidasen nachgewiesen, was zu entsprechenden 
Symptomen mit Diarrhoe, Blähungen und Abdominalschmerzen führt (Gonzalez-
Galan, Sanchez-Fauqier et al., 2011; Khanna, Vinayak et al., 1988; Rana, Bhasin et 
al., 2005). Aufgrund von dieser Erkenntnisse wollten wir die Hypothese überprüfen, 
ob der Diarrhoe bei einer chronischen Norovirus-Infektion ebenfalls ein 
Laktasemangel zugrunde liegen könnte. 
Der primäre Endpunkt dieser Arbeit war es daher, die Inzidenz einer 
Lactosemaldigestion bei Patienten mit symptomatischer chronischer 
Norovirusinfektion im Vergleich zu Patienten mit chronischer Diarrhoe aufgrund einer 
anderen Ursache zu untersuchen. Da chronische Norovirusinfektionen v.a. bei 
immunsupprimierten Patienten auftreten, wurden ausschliesslich 
nierentransplantierte Patienten in die Studie eingeschlossen.  
Patientenkollektiv, Methoden, Datenauswertung und Statistik 
 
Patientenkollektiv 
Im Zeitraum zwischen Juli 2013 und März 2015 wurden alle erwachsenen 
Nierentransplantationspatienten am Universitätsspital Zürich, bei denen eine 
chronische Norovirusinfektion mit Diarrhoe vorlag, angefragt, an der vorliegenden 
prospektiven, parallellaufenden Kohortenstudie teilzunehmen. In Übereinstimmung 
mit den Kriterien der Weltgesundheitsorganisation (WHO) wurde eine chronische 
Diarrhoe als das Vorliegen von mindestens drei Stuhlentleerungen am Tag über 
einen Zeitraum von mindestens vier Wochen definiert. Das Kriterium für eine 
chronische Norovirusinfektion war der Nachweis von Noroviren durch die 
Polymerasekettenreaktion (PCR) in mehr als zwei Stuhlproben über einen Zeitraum 
von mindestens einem Monat. Als Vergleichsgruppe dienten nierentransplantierte 
Patienten mit einer chronischen Diarrhoe ohne Nachweis einer Norovirusinfektion 
oder einer anderen Infektion.  
Ausschlusskriterien für die Teilnahme an der Studie waren: 
- Eine Darminfektion durch Infekterreger wie Viren (ausser Norovirus), 
Bakterien (Salmonellen, Campylobacter und Shigellen) oder Parasiten 
(besonders Gardia lamblia, Microspora spp., and Cryptospora spp.) 
nachgewiesen durch Polymerasekettenreaktion (PCR), Kultur oder 
mikroskopische Untersuchung. Eine Cytomegalievirusinfektion wurde mittels 
PCR im Blut sowie Koloskopie mit Histologie ausgeschlossen.  
- Eine primäre adulte Laktosemalabsorption bzw. eine primäre 
Laktoseintoleranz definiert als molekulargenetischer Nachweis des CC-
Genotyps des C/T-13910-Polymorphismus vor dem 5’-Ende des Laktasegens.  
- Eine bekannte Galaktosämie oder Notwendigkeit einer galaktosearmen Diät. 
Kriterien für die Aufnahme in die Kontrollgruppe waren: 
- Alter > 18 Jahre 
- Zustand nach einer Nierentransplantation  
- Vorliegen einer chronischen Diarrhoe unklarer Ursache 
- Ausschluss einer Norovirusinfektion sowie anderer viraler, bakterieller und 
parasitärer Darminfektionen durch PCR bzw. Kultur oder mikroskopische 
Untersuchung. 
Der Auftrag des Doktorierenden beim Patientenkollektiv bestand darin sämtliche 
Patienten anhand der gewählten Kriterien in einer Excel-Tabelle festzuhalten und zu 
rekrutieren.  
Methode 
Laktose H2-Atemtest und Laktosetoleranztest 
Bei allen Patienten wurde ein Laktose H2-Atemtest und ein oraler 
Laktosetoleranztest durchgeführt. Das Kriterium für die Diagnose einer 
Laktosemaldigestion war ein pathologisches Ergebnis beim H2-Atemtest und/oder 
dem oralen Laktosetoleranztest. 
Laktose H2-Atemtest  
Der Laktose H2-Atemtest (LH2BT) wurde gemäß Newcomer et al. (Newcomer, 
McGill et al., 1975) durchgeführt. Nach nächtlichem Fasten über mindestens 12 
Stunden wurde eine basale Atemprobe (Nüchternprobe) abgenommen. Während der 
Fastenzeit durften die Patienten Wasser trinken. Die übliche Medikation wurde 
während der gesamten Untersuchung weitergeführt. Nach der Abnahme der 
Nüchternprobe tranken die Patienten 50 g Laktose gelöst in 250 ml Wasser. Proben 
von 20ml der endexspiratorischen Atemluft wurden jeweils 30, 60, 90 und 120 
Minuten nach der oralen Laktosebelastung mit dem AlveoSampler™ Lactose Kit 
(Quintron Instrument Co., Milwaukee, WI, USA) gesammelt. Eine H2-Konzentration 
von mehr als 20 parts per million (ppm) wurde als Kriterium für das Vorliegen einer 
Laktosemaldigestion gewertet (Gasbarrini, Corazza et al., 2009; Newcomer, McGill et 
al., 1975). Während der Untersuchung durften die Patienten nicht essen, sonst aber 
ihren üblichen Aktivitäten nachgehen ohne den Laborraum zu verlassen. Das Trinken 
von Wasser war jederzeit erlaubt. Die Untersuchung wurde in einem gut gelüfteten 
Raum durchgeführt. Zigarettenrauch, frisch gestrichene Wände oder sonstige frisch 
gestrichene Gegenstände und organische Lösungsmittel waren nicht vorhanden. Die 
Proben der Atemluft wurden in speziell hierfür konstruierten Taschen gesammelt, die 
zusammen mit dem Messgerät von der Klinik für Gastroenterologie USZ zur 
Verfügung gestellt wurden. Die Wasserstoff-Konzentration wurde dann mit dem 
Gerät 12i Microlyser (Quintron Instrument Co., Milwaukee, WI, USA) gemessen. 
Während der Untersuchungsperiode wurde aufgezeichnet, wie oft es zu 
Stuhlentleerungen und zum Abgang von Darmgasen kam, oder ob der Patient an 
Abdominalbeschwerden litt. 
Laktosetoleranztest  
Gleichzeitig an die oben beschriebene orale Verabreichung wurden die 
Blutzuckerwerte im Kapillarblut bei 0, 60 und 120 Minuten mit Hilfe eines 
Blutzuckermessgeräts (Accu-Chek Roche Diabetes Care (Schweiz) AG) bestimmt. 
Ein Anstieg des Blutzuckerspiegels von weniger als 1,1 mmol/l in Verbindung mit 
dem Auftreten von Abdominalbeschwerden wurde als beweisend für das Vorliegen 
einer Laktoseintoleranz definiert (Newcomer, McGill et al., 1975). 
Der Auftrag des Doktorierenden bestand zunächst in der Motivation und Einplanung 
der Patienten im Gastroenterologie-Labor am USZ sowie die Patienten am 
Untersuchungstag am Empfang abzuholen und mit ihnen die oben beschriebenen 
Untersuchungen im Labor selbstständig durchzuführen, nachdem die 
Einverständniserklärung eingeholt worden war. Die entstandenen Daten wurden in 
einem zuvor selber erstellten, für diese Arbeit zweckmässigen Protokoll erfasst. Alle 
Patienten wurden durch den Doktorierenden während der ganzen Untersuchung 
persönlich betreut. Im Falle eines positiven Testergebnisses wurde in Absprache mit 
einem Oberarzt der Nephrologie eine Empfehlung zur Ernährungsberatung dem 
Patienten unterbreitet und gegebenenfalls Instruktionen über die genetische 
Untersuchung erteilt sowie einholen der Unterschrift dazu veranlasst. 
Datenauswertung und Statistik 
Bei der deskriptiven Darstellung der Basisdaten wurde bei metrischen Parametern 
Median und Interquartilenbereich (IQR) berechnet. Die Berechnung von 
Unterschieden zwischen beiden Studiengruppen wurde bei metrischen Daten ein 
zweiseitiger Mann-Whitney U-Test eingesetzt. Bei kategorialen Variablen wurde die 
absolute Häufigkeit (n) und die relative Häufigkeit (%) bestimmt. Zur Überprüfung der 
Unabhängigkeit kategorialer Variablen wurde der Chi-Quadrat-Test eingesetzt. 
Die Wasserstoffkonzentration in der Ausatmungsluft und der Blutzuckerspiegel 
wurden als Median und Interquartilenbereich (IQR) angegeben. Unterschiede 
zwischen verschiedenen Zeitpunkten wurden mit Hilfe des Wilcoxon-
Rangsummentests für verbundene Stichproben berechnet. Als Signifikanzniveau 
wurde bei allen Test p < 0,05 festgelegt. Alle statistischen Berechnungen und 
grafischen Darstellungen wurden unter Verwendung des Programms SPSS Statistics 
für Windows, Version 22 (IBM Corporation, Armonk, NY) erstellt. 
Der Auftrag des Doktorierenden war das selbstständige Erstellen der deskriptiven 
Statistik sowie einen Flow-Chart über den Patientenfluss zu erstellen. Zudem wurde 
die induktive Statistik mit Hilfe von Dr. med. Franzen durchgeführt.  
Resultate 
 
Von den etwa achthundert Patienten in der Kohorte der erwachsenen 
Nierentransplantationspatienten des Universitätsspitals Zürich wurden insgesamt 15 
Patienten in die Studie eingeschlossen. Sieben dieser Patienten hatten eine 
chronische symptomatische Norovirus-Infektion mit Diarrhöe (Noro-Gruppe). Die 
Kontrollgruppe umfasste acht Patienten. Die Zusammensetzung des 
Patientenkollektivs ist in der Publikation Figure 1 (Study flow chart) dargestellt. 
Die demografischen und klinischen Basisdaten sind in Table 1 zusammengefasst. 
„Baseline characteristics“, die laborchemischen Basisdaten sind in Table 2 
ersichtlich. Die Zytomegalie-Hochrisiko-Konstellation war in der Kontrollgruppe 
signifikant häufiger als in der Noro-Gruppe (p = 0,013). Bei allen anderen Variablen 
(Alter, Geschlecht, Art und Dosierung der Immunsuppression, Häufigkeit eines 
Diabetes mellitus, Laborwerte) gab es keinen signifikanten Unterschied zwischen der 
Noro-Gruppe und der Kontrollgruppe. Während des Untersuchungszeitraums erhielt 
kein Patient Antibiotika.  
In der Noro-Gruppe fiel der Laktose H2-Atemtest und der Laktosetoleranztest bei 
allen Patienten positiv aus, wobei die H2-Konzentration in der Ausatmungsluft 120 
Minuten nach der Laktosegabe bei über 20 ppm lag. In der Kontrollgruppe fielen bei 
lediglich einem Patienten sowohl der Laktose H2-Atemtest als auch der 
Laktosetoleranztest positiv aus. Bei den anderen sieben Patienten der 
Kontrollgruppe ergaben der Laktose H2-Atemtest und der Laktosetoleranztest 
Normalwerte. 
Bei sechs der sieben Patienten in der Noro-Gruppe (85,7%) traten nach der 
Laktosegabe abdominelle Beschwerden auf. Hierbei handelte es sich bei drei 
Patienten um eine Diarrhoe und bei drei Patienten um Meteorismus. In der 
Kontrollgruppe traten bei keinem Patienten Abdominalbeschwerden auf. Hierzu 
zählte auch der Patient mit einem positiven Laktose H2-Atemtest und 
Laktosetoleranztest. 
Aufgrund des Laktose H2-Atemtest und Laktosetoleranztest (Tabelle 1) war die 
Laktosemaldigestion in der Noro-Gruppe signifikant häufiger als in der Kontrollgruppe 
(Odds Ratio 75%, 95% CI 2.6, 2153, p = 0.01). 
Tabelle 1 Testergebnisse des Laktose H2-Atemtests und Laktosetoleranztests 
(vgl. Publikation) 
 Noro-Gruppe (n=7) Kontroll-Gruppe (n=8) 
LHBT / LTT positive 7 (100) 1 (12.5) 




Die mögliche Korrelation zwischen Norovirusinfektion und Laktasemangel spricht 
dafür, dass die Diarrhoe bei immunsupprimierten Patienten mit einer chronischen 
Norovirusinfektion durch eine sekundäre Laktosemaldigestion hervorgerufen oder 
unterhalten werden könnte. Zur abschließenden Klärung dieses Zusammenhangs ist 
eine placebokontrollierte Doppelblindstudie an einer größeren Patientenzahl 
erforderlich. Hierbei sollte auch die Auswirkung einer laktosearmen Diät untersucht 
werden. 
Der Auftrag des Doktorierenden war schlussendlich das Erstellen eines ersten Drafts 
des Manuskriptes.  
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